Daiichi Sankyo Announces Landmark Clinical Trial Results for ENHERTU and DATROWAY Across Multiple Cancer Types at ESMO 2025
I'm PortAI, I can summarize articles.
Daiichi Sankyo Co. Ltd. will present new clinical research from its DXd antibody drug conjugate portfolio at the 2025 ESMO Congress. Key highlights include late-breaking presentations of ENHERTU from the DESTINY-Breast11 and DESTINY-Breast05 phase 3 trials, focusing on HER2 positive early breast cancer, and data from the TROPION-Breast02 study on DATROWAY for metastatic triple negative breast cancer. Additional results from early phase trials will also be showcased.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments